Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 5, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding shareholding changes within a specific employee fund and does not contain financial performance data.
Material Changes
The only material change disclosed is a reduction in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 18,440,842 ADRs
- New Holding: 18,416,461 ADRs
- Change Date: December 1, 2005
- Average Price: $50.45
The change resulted from a movement in the fund. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in these shares as beneficiaries of the discretionary fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific transaction under Disclosure Rule 3.1.4R (1) (b).
Key Facts for Investor Verification
- Verify the impact of the fund movement on the total share count held by the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not reflect operational or financial performance for the period.